title: Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up.
authors.affiliation: Division of Urologic Surgery/Transplantation, University of Pittsburgh Medical Center, PA 15213, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Jordan
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: C
authors.initials: C
authors.lastname: Vivas
authors.forename: V
authors.initials: V
authors.lastname: Scantlebury
authors.forename: J
authors.initials: J
authors.lastname: McCauley
authors.forename: J
authors.initials: J
authors.lastname: McMichael
authors.forename: P
authors.initials: P
authors.lastname: Randhawa
authors.forename: A
authors.initials: A
authors.lastname: Demetris
authors.forename: J
authors.initials: J
authors.lastname: Fung
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus